Evidence map›Paper›PMID 20039801›Full record

ArticleThe Journal of infectious diseases2010

A case of seronegative HIV-1 infection.

Adam M Spivak, Tim P Brennan, Karen A O'Connell, Emily Sydnor, Thomas M Williams, Robert F Siliciano, Joel E Gallant, Joel N Blankson

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Adam M SpivakDepartment of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. jblanks@jhmi.edu
Tim P Brennan
Karen A O'Connell
Emily Sydnor
Thomas M Williams
Robert F Siliciano
Joel E Gallant
Joel N Blankson
Johns Hopkins Medicine · USJohns Hopkins University · US

Funding

CD8+ T cell mediated inhibition of HIV-1 replication in Elite SuppressorsR01AI080328 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BLANKSON, JOEL N · 2009 to 2012
$1.3M
CD8+ T cell mediated inhibition of HIV-1 replication in Elite SuppressorsR56AI080328 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BLANKSON, JOEL N · 2014 to 2014
$405k
Characterization of HIV excape mutants and T cell responses in elite suppressorsR56AI073185 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BLANKSON, JOEL N · 2007 to 2007
$281k
Howard Hughes Medical InstituteNIAID NIH HHS R01 AI080328NIAID NIH HHS R56 AI073185NIAID NIH HHS R56 AI73185-01A1
6 · The paper itself

Abstract

Patients infected with human immunodeficiency virus type 1 (HIV-1) typically seroconvert within weeks of primary infection. In rare cases, patients do not develop antibodies against HIV-1 despite demonstrable infection. We describe here a human leukocyte antigen (HLA)-B*5802-positive individual who presented with acquired immune deficiency syndrome despite repeatedly negative HIV-1 antibody screening test results. Phylogenetic analysis of env clones revealed little sequence diversity, and weak HIV-1-specific CD8(+) T cell responses were present to Gag epitopes. The patient seroconverted after immune reconstitution during receipt of highly active antiretroviral therapy. Lack of an antibody response to HIV-1 is rare and appears to be due to a defect in HIV-1-specific immunity rather than infection with attenuated virus.

Indexed as

Base SequenceGene Products, envHIV-1HIV AntibodiesHIV InfectionsHIV SeronegativityHumansMaleMiddle AgedGene Products, envHIV Antibodies

Identifiers

PMID20039801
PMCPMC2821828
OpenAlexW2115754775

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.